Authors
Latest:
ASCO President Recaps Top Stories From MeetingDr. Michael P. Link, ASCO President, from Stanford University School of Medicine, on the top stories from the 2012 ASCO Annual Meeting.
Latest:
Dr. Palese on Emerging Technologies in Benign Prostatic HyperplasiaMichael A. Palese, MD, discusses emerging technologies in benign prostatic hyperplasia.
Latest:
Dr. Pishvaian Discusses Atezolizumab Plus Bevacizumab in HCCMichael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with hepatocellular carcinoma.
Latest:
The Future of Metastatic and Unresectable Melanoma TreatmentThe panel concludes their discussion with a call for continued research and collaboration, emphasizing the need for more understanding of targeted therapies, monitoring tools like ctDNA, and ongoing development in the field of BRAF mutant melanoma treatment.
Latest:
Pivotal Data in NHL and Pediatric Cancers at ASH 2021: Insight From Drs. Loretta Nastoupil and Michael PulsipherOncLive speaks with Dr. Loretta Nastoupil on some exciting non-Hodgkin lymphoma studies and Dr. Michael Pulsipher on some intriguing pediatric cancer research.
Latest:
Dr Bishop on the Utility of Obe-Cel in Relapsed/Refractory B-ALLMichael R. Bishop, MD, discusses the FELIX study, highlighting the safety of obe-cel in B-cell acute lymphoblastic leukemia.
Latest:
Dr. Charlton on the Interaction Between Liver Disease and HCCMichael R. Charlton, MD, MBBS, discusses the interaction between liver disease and hepatocellular carcinoma.
Latest:
Dr. Harrison on the Investigation of Combination Strategies in Frontline RCCMichael R. Harrison, MD, discusses several ongoing or upcoming studies that may change the treatment paradigm in renal cell carcinoma.
Latest:
Chemotherapy Parity Laws Ignore Cost, Quality QuestionWith the FDA approval of several oral chemotherapy agents, the cost of medications to treat cancer is increasing rapidly. To control costs, legislators, patient advocates, and physicians have pushed for oral chemotherapy parity laws.
Latest:
Dr. Rosenzweig Discusses the Standard of Care in AmyloidosisMichael Rosenzweig, MD, assistant professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses the standard of care for the treatment of patients with amyloidosis.
Latest:
Dr. Rotkowitz Describes Challenges Facing ImmunotherapyMichael Rotkowitz, MD, says that one of the main challenges and a leading goal of immunotherapy research is measuring response to justify the administration.
Latest:
Dr. Ewer Discusses Supportive CareDr. Michael S. Ewer, from The University of Texas MD Anderson Cancer Center, on Supportive Care
Latest:
Dr. Lee on Trial Data Evaluating the Atezolizumab/Bevacizumab in Unresectable HCCMichael S. Lee, MD, discusses trial data evaluating the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in unresectable hepatocellular carcinoma.
Latest:
Dr. Sawyer on LBM Outcomes With Siltuximab in Multicentric Castleman's DiseaseMichael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass (LBM) outcomes in patients with multicentric Castleman's disease who received siltuximab (Sylvant).
Latest:
Dr. Simon on Genomic Assays for Patients With Breast CancerMichael Simon, MD, MPH, medical oncologist, Karmanos Cancer Institute, discusses genomic assays for patients with breast cancer.
Latest:
Payer Management of Oncology Gets SeriousHealth plans continue to seek methods to curtail cancer costs.
Latest:
Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?A retrospective experience suggests that early glottic cancer treated with HRT results in a higher incidence of acute toxicity without improved control compared to CRT delivered in an appropriate OTT.
Latest:
Dr. Ulm on Trial for Postoperative Pain Management in Gynecological CancerMichael Ulm, MD, fellow, University of Tennessee Health Science Center, West Cancer Center, discusses the rationale and results of a trial for postoperative pain management in gynecological cancer.
Latest:
Dr. Untch on the Expanding Use of BiosimilarsMichael Untch, MD, PhD, discusses the widespread use of biosimilars in Europe.
Latest:
Protect Yourself From Malpractice ClaimsCompared with other specialists, medical oncologists are not often the target of malpractice litigation. Even so, they still get sued.
Latest:
Ibrutinib Combined With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results From the Randomized Phase 3 SYMPATICO StudyMichael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).
